TISIDB

Summary
Symbol	IFNB1
Name	interferon, beta 1, fibroblast
Aliases	IFB; IFF; IFNB; IFN-beta; fibroblast interferon; Interferon beta
Chromosomal Location	9p22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Secreted.
Domain	PF00143 Interferon alpha/beta domain
Function	Has antiviral, antibacterial and anticancer activities.

> Gene Ontology [ TOP ]
Biological Process	GO:0001818 negative regulation of cytokine production GO:0001959 regulation of cytokine-mediated signaling pathway GO:0002250 adaptive immune response GO:0002263 cell activation involved in immune response GO:0002285 lymphocyte activation involved in immune response GO:0002286 T cell activation involved in immune response GO:0002312 B cell activation involved in immune response GO:0002323 natural killer cell activation involved in immune response GO:0002366 leukocyte activation involved in immune response GO:0002367 cytokine production involved in immune response GO:0002369 T cell cytokine production GO:0002440 production of molecular mediator of immune response GO:0002443 leukocyte mediated immunity GO:0002449 lymphocyte mediated immunity GO:0002456 T cell mediated immunity GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002521 leukocyte differentiation GO:0002683 negative regulation of immune system process GO:0002694 regulation of leukocyte activation GO:0002695 negative regulation of leukocyte activation GO:0002697 regulation of immune effector process GO:0002698 negative regulation of immune effector process GO:0002700 regulation of production of molecular mediator of immune response GO:0002701 negative regulation of production of molecular mediator of immune response GO:0002703 regulation of leukocyte mediated immunity GO:0002704 negative regulation of leukocyte mediated immunity GO:0002706 regulation of lymphocyte mediated immunity GO:0002707 negative regulation of lymphocyte mediated immunity GO:0002709 regulation of T cell mediated immunity GO:0002710 negative regulation of T cell mediated immunity GO:0002718 regulation of cytokine production involved in immune response GO:0002719 negative regulation of cytokine production involved in immune response GO:0002724 regulation of T cell cytokine production GO:0002725 negative regulation of T cell cytokine production GO:0002819 regulation of adaptive immune response GO:0002820 negative regulation of adaptive immune response GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002823 negative regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002828 regulation of type 2 immune response GO:0002829 negative regulation of type 2 immune response GO:0006959 humoral immune response GO:0007159 leukocyte cell-cell adhesion GO:0007162 negative regulation of cell adhesion GO:0007259 JAK-STAT cascade GO:0007596 blood coagulation GO:0007599 hemostasis GO:0009615 response to virus GO:0018105 peptidyl-serine phosphorylation GO:0018209 peptidyl-serine modification GO:0019058 viral life cycle GO:0019079 viral genome replication GO:0022407 regulation of cell-cell adhesion GO:0022408 negative regulation of cell-cell adhesion GO:0030098 lymphocyte differentiation GO:0030101 natural killer cell activation GO:0030183 B cell differentiation GO:0030217 T cell differentiation GO:0031349 positive regulation of defense response GO:0031960 response to corticosteroid GO:0032943 mononuclear cell proliferation GO:0033135 regulation of peptidyl-serine phosphorylation GO:0033138 positive regulation of peptidyl-serine phosphorylation GO:0033139 regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0034340 response to type I interferon GO:0035456 response to interferon-beta GO:0035458 cellular response to interferon-beta GO:0035743 CD4-positive, alpha-beta T cell cytokine production GO:0035745 T-helper 2 cell cytokine production GO:0042092 type 2 immune response GO:0042100 B cell proliferation GO:0042110 T cell activation GO:0042113 B cell activation GO:0042501 serine phosphorylation of STAT protein GO:0042742 defense response to bacterium GO:0043330 response to exogenous dsRNA GO:0043331 response to dsRNA GO:0043900 regulation of multi-organism process GO:0043901 negative regulation of multi-organism process GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism GO:0045069 regulation of viral genome replication GO:0045071 negative regulation of viral genome replication GO:0045088 regulation of innate immune response GO:0045089 positive regulation of innate immune response GO:0045341 MHC class I biosynthetic process GO:0045343 regulation of MHC class I biosynthetic process GO:0045580 regulation of T cell differentiation GO:0045581 negative regulation of T cell differentiation GO:0045619 regulation of lymphocyte differentiation GO:0045620 negative regulation of lymphocyte differentiation GO:0046425 regulation of JAK-STAT cascade GO:0046651 lymphocyte proliferation GO:0048525 negative regulation of viral process GO:0048545 response to steroid hormone GO:0050777 negative regulation of immune response GO:0050792 regulation of viral process GO:0050817 coagulation GO:0050863 regulation of T cell activation GO:0050865 regulation of cell activation GO:0050866 negative regulation of cell activation GO:0050868 negative regulation of T cell activation GO:0050878 regulation of body fluid levels GO:0051249 regulation of lymphocyte activation GO:0051250 negative regulation of lymphocyte activation GO:0051384 response to glucocorticoid GO:0051607 defense response to virus GO:0060337 type I interferon signaling pathway GO:0060338 regulation of type I interferon-mediated signaling pathway GO:0060759 regulation of response to cytokine stimulus GO:0070486 leukocyte aggregation GO:0070489 T cell aggregation GO:0070661 leukocyte proliferation GO:0071357 cellular response to type I interferon GO:0071359 cellular response to dsRNA GO:0071360 cellular response to exogenous dsRNA GO:0071383 cellular response to steroid hormone stimulus GO:0071384 cellular response to corticosteroid stimulus GO:0071385 cellular response to glucocorticoid stimulus GO:0071396 cellular response to lipid GO:0071407 cellular response to organic cyclic compound GO:0071548 response to dexamethasone GO:0071549 cellular response to dexamethasone stimulus GO:0071593 lymphocyte aggregation GO:0097696 STAT cascade GO:0098542 defense response to other organism GO:0098586 cellular response to virus GO:1901654 response to ketone GO:1901655 cellular response to ketone GO:1902105 regulation of leukocyte differentiation GO:1902106 negative regulation of leukocyte differentiation GO:1903037 regulation of leukocyte cell-cell adhesion GO:1903038 negative regulation of leukocyte cell-cell adhesion GO:1903706 regulation of hemopoiesis GO:1903707 negative regulation of hemopoiesis GO:1903900 regulation of viral life cycle GO:1903901 negative regulation of viral life cycle GO:1904892 regulation of STAT cascade GO:2000551 regulation of T-helper 2 cell cytokine production GO:2000552 negative regulation of T-helper 2 cell cytokine production GO:2001233 regulation of apoptotic signaling pathway GO:2001235 positive regulation of apoptotic signaling pathway
Molecular Function	GO:0005125 cytokine activity GO:0005126 cytokine receptor binding GO:0005132 type I interferon receptor binding GO:0008374 O-acyltransferase activity GO:0008811 chloramphenicol O-acetyltransferase activity GO:0016407 acetyltransferase activity GO:0016413 O-acetyltransferase activity GO:0016746 transferase activity, transferring acyl groups GO:0016747 transferase activity, transferring acyl groups other than amino-acyl groups
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04060 Cytokine-cytokine receptor interaction hsa04151 PI3K-Akt signaling pathway hsa04380 Osteoclast differentiation hsa04620 Toll-like receptor signaling pathway hsa04621 NOD-like receptor signaling pathway hsa04622 RIG-I-like receptor signaling pathway hsa04623 Cytosolic DNA-sensing pathway hsa04630 Jak-STAT signaling pathway hsa04650 Natural killer cell mediated cytotoxicity
Reactome	R-HSA-2559583: Cellular Senescence R-HSA-2262752: Cellular responses to stress R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-983231: Factors involved in megakaryocyte development and platelet production R-HSA-109582: Hemostasis R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-913531: Interferon Signaling R-HSA-909733: Interferon alpha/beta signaling R-HSA-2559580: Oxidative Stress Induced Senescence R-HSA-168928: RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways R-HSA-912694: Regulation of IFNA signaling R-HSA-918233: TRAF3-dependent IRF activation pathway R-HSA-933541: TRAF6 mediated IRF7 activation

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04060 Cytokine-cytokine receptor interaction
hsa04151 PI3K-Akt signaling pathway
hsa04380 Osteoclast differentiation
hsa04620 Toll-like receptor signaling pathway
hsa04621 NOD-like receptor signaling pathway
hsa04622 RIG-I-like receptor signaling pathway
hsa04623 Cytosolic DNA-sensing pathway
hsa04630 Jak-STAT signaling pathway
hsa04650 Natural killer cell mediated cytotoxicity

Reactome

R-HSA-2559583: Cellular Senescence
R-HSA-2262752: Cellular responses to stress
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-983231: Factors involved in megakaryocyte development and platelet production
R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-913531: Interferon Signaling
R-HSA-909733: Interferon alpha/beta signaling
R-HSA-2559580: Oxidative Stress Induced Senescence
R-HSA-168928: RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
R-HSA-912694: Regulation of IFNA signaling
R-HSA-918233: TRAF3-dependent IRF activation pathway
R-HSA-933541: TRAF6 mediated IRF7 activation

Summary
Symbol	IFNB1
Name	interferon, beta 1, fibroblast
Aliases	IFB; IFF; IFNB; IFN-beta; fibroblast interferon; Interferon beta
Chromosomal Location	9p22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between IFNB1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between IFNB1 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
28483787	Breast Neoplasm	Promote immunity (T cell function)	Stimulator of interferon genes (STING) signaling induces IFNβ production by intratumoral dendritic cells (DC), driving T-cell priming and recruitment into the tumor microenvironment (TME).
23636788	Lung Carcinoma; Prostate Carcinoma	Promote immunity	We describe here a novel effect of dsRNA analogs on cancer cells: besides their potential to induce cancer cell apoptosis through an IFN-β autocrine loop, dsRNA-elicited IFN-β production improves dendritic cell (DC) functionality. Human A549 lung and DU145 prostate carcinoma cells significantly responded to poly I:C stimulation, producing IFN-β at levels that were capable of activating STAT1 and enhancing CXCL10, CD40, and CD86 expression on human monocyte-derived DCs.
17374743	Myeloid Leukemia	Promote immunity (T cell function)	Ubp43 is an ISG15-specific isopeptidase, the expression of which is activated by IFN. Ubp43 deficiency increases the resistance to oncogenic transformation by BCR-ABL. This resistance to leukemic development is dependent on type 1 IFN (IFN-alpha/beta) signaling in Ubp43-deficient cells. These results suggest that inhibition of Ubp43-negative effect on IFN signaling can potentiate the response to increased endogenous IFN levels in innate immune responses against cancer development, indicating that pharmacological inhibition of Ubp43 may be of benefit in cancers and others diseases in which interferon is currently prescribed.
24806531	Melanoma; Breast Carcinoma	Promote immunity	Here, we provide evidence that endogenous IFN-β is regulating the apoptosis of pro-angiogenic tumor infiltrating neutrophils by influencing both, the extrinsic as well as the intrinsic apoptosis pathways. Accordingly, the life span of tumor associated neutrophils (TANs) is remarkably prolonged in tumor bearing Ifnb1(-/-) mice compared to wild type controls. Lower expression of Fas, reactive oxygen species, active Caspase 3 and 9, as well as a change in expression pattern of proapoptotic and antiapoptotic members of the Bcl-2 family and the major apoptosome constituent Apaf-1 is observed under such conditions. In line with inhibition of apoptosis and the prolonged neutrophil survival,
21482773	Breast Carcinoma (ERBB-(+))	Promote immunity (T cell function); essential for immunotherapy	We report here that anti-ErbB-2 mAb therapy is dependent on the release of type I and type II IFNs but is independent of perforin or FasL.
29229854	Triple-Negative Breast Carcinoma	Promote immunity	Treatment with IFN-beta (IFN-β) led to a less aggressive epithelial/non-CSC-like state, with repressed expression of mesenchymal proteins (VIMENTIN, SLUG), reduced migration and tumor sphere formation, and reexpression of CD24 (a surface marker for non-CSCs), concomitant with an epithelium-like morphology. Here we report a positive translational role for IFN-β, as gene expression profiling of patient-derived TNBC tumors demonstrates that an IFN-β metagene signature correlates with improved patient survival, an immune response linked with tumor-infiltrating lymphocytes (TILs), and a repressed CSC metagene signature.
17675472	Melanoma	Promote immunity	IFN-beta (but neither IFN-alpha nor IFN-gamma) augmented both protein and mRNA expression of melanocytic TAA in 15 melanoma lines (irrespective of initial Ag-expression levels). Treatment of low Ag melanoma lines with IFN-beta increased expression of melanocyte-lineage Ags, inducing susceptibility to lysis by specific CTLs. Treatment with IFN-beta also enhances expression of class I HLA molecules, thereby inducing both nominal TAA and the presenting HLA molecule. Data from fluorescent cellular reporter systems demonstrated that IFN-beta triggers promoter activation, resulting in augmentation of Ag expression.
21930769	fibrosarcoma	Promote immunity	We recently have reported that targeting low doses of IFN-beta to the tumor microenvironment using tumor-specific mAbs can facilitate antitumor immunity, which could be augmented further with PD-L1/PD-1 blockade
21930769	Fibrosarcoma	Promote immunity	Herein, we show that type I IFN is required to initiate the antitumor response and that its actions are temporally distinct from IFN-γ during cancer immunoediting.
16951315	Melanoma	Promote immunity	Even though the expression of surface markers for DC activation ex vivo did not always reach the level attained by an optimized amount of LPS, superior antitumor effects to B16F1 melanoma, namely tumor elimination and survival, were obtained with use of SeV-GFP/DC as compared with those seen with LPS/DC in vivo, and the effect was enhanced by SeV/DC-expressing IFN-beta (SeV-murine IFN-beta (mIFN-beta)/DC).

Summary
Symbol	IFNB1
Name	interferon, beta 1, fibroblast
Aliases	IFB; IFF; IFNB; IFN-beta; fibroblast interferon; Interferon beta
Chromosomal Location	9p22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of IFNB1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	IFNB1
Name	interferon, beta 1, fibroblast
Aliases	IFB; IFF; IFNB; IFN-beta; fibroblast interferon; Interferon beta
Chromosomal Location	9p22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of IFNB1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0	1
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0	1
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0	1
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-1.153	0.305
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.693	0.668
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-3.505	0.0914
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0	1
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0	1
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0	1
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0	1
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0	1
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.184	0.194

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of IFNB1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	1.4	2.3	0.469
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	1.7	2	0.532
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	IFNB1
Name	interferon, beta 1, fibroblast
Aliases	IFB; IFF; IFNB; IFN-beta; fibroblast interferon; Interferon beta
Chromosomal Location	9p22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IFNB1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	IFNB1
Name	interferon, beta 1, fibroblast
Aliases	IFB; IFF; IFNB; IFN-beta; fibroblast interferon; Interferon beta
Chromosomal Location	9p22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IFNB1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IFNB1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	IFNB1
Name	interferon, beta 1, fibroblast
Aliases	IFB; IFF; IFNB; IFN-beta; fibroblast interferon; Interferon beta
Chromosomal Location	9p22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IFNB1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	IFNB1
Name	interferon, beta 1, fibroblast
Aliases	IFB; IFF; IFNB; IFN-beta; fibroblast interferon; Interferon beta
Chromosomal Location	9p22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of IFNB1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	IFNB1
Name	interferon, beta 1, fibroblast
Aliases	IFB; IFF; IFNB; IFN-beta; fibroblast interferon; Interferon beta
Chromosomal Location	9p22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between IFNB1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	IFNB1
Name	interferon, beta 1, fibroblast
Aliases	IFB; IFF; IFNB; IFN-beta; fibroblast interferon; Interferon beta
Chromosomal Location	9p22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting IFNB1 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting IFNB1.

ID	Name	Drug Type	Targets	#Targets
DB02379	Beta-D-Glucose	Small Molecule	AMY1A, AMY2A, AMY2B, GCK, GLT6D1, GNPDA1, HK1, IFNB1, KRTAP5-2, KR ......	22

Browse IFNB1